Research ArticleClinical Studies
Open Access

Molecular Hydrogen Therapy in Sjögren’s Syndrome With Pulmonary Arterial Hypertension and Right-sided Heart Failure: A Case Report of Improved Immune Markers Including Treg, B Cells and Plasma Cell

YUN-TING LIN, JENG-WEI LU, CHUN-HSIEN WU, YI-JUNG HO, SHAN-WEN LUI, TING-YU HSIEH and FENG-CHENG LIU
In Vivo November 2024, 38 (6) 3117-3124; DOI: https://doi.org/10.21873/invivo.13797

Abstract

Background/Aim: Connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) is a severe complication characterized by elevated pulmonary artery pressure, which can lead to right heart failure and death, if untreated. Standard treatments often fail to adequately manage symptoms, highlighting the need for novel therapeutic approaches. This study investigated the efficacy of molecular hydrogen (H2) therapy in a patient with CTD-PAH. Case Report: We present the case of a 56-year-old female with CTD-PAH, diagnosed in 2013 with Sjogren’s syndrome complicated by interstitial lung disease (ILD) and PAH. Despite treatment with sildenafil, bosentan, macitentan, iloprost, and corticosteroids, her condition deteriorated, resulting in severe dyspnea and cardiogenic shock in 2020. In May 2023, molecular hydrogen therapy was initiated as an adjuvant treatment. The patient received daily hydrogen capsules, which led to increased CD127+ Treg cells, reduced anti-Ro antibodies, and decreased B cell subsets. Her clinical symptoms stabilized without adverse effects. Conclusion: This case highlights the potential benefits of molecular hydrogen therapy in CTD-PAH. H2 therapy exhibiting anti-inflammatory and immunomodulatory effects, leading to improved immune cell profiles and stabilizing clinical symptoms in a patient unresponsive to conventional treatments. Further research is needed to elucidate the mechanisms of H2 therapy and validate its efficacy in larger cohorts. Molecular hydrogen therapy shows promise as a safe adjunctive treatment for CTD-PAH, offering a new approach for managing this challenging condition.

Key Words:

Connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) presents significant challenges in clinical management due to its complex pathogenesis and potential life-threatening consequences if left untreated (1). Among the various connective tissue diseases (CTDs) implicated, Sjogren’s syndrome stands out as a notable contributor to CTD-PAH (2). PAH, characterized by elevated pressure in the pulmonary arteries, poses a risk of right heart failure and increased mortality if left untreated (3). The pathogenesis of PAH within the context of CTDs involves a complex interplay of immune-mediated vascular damage, chronic inflammation, and fibrosis (4). Common symptoms of CTD-PAH include dyspnea, fatigue, chest pain, and syncope, necessitating a multidisciplinary approach to management (5). Current therapeutic strategies for CTD-PAH encompass both immunosuppressive therapies and PAH-specific treatments. Immunosuppressive therapy, including corticosteroids and disease-modifying antirheumatic drugs (DMARDs), aims to control inflammation and manage the underlying CTD (6). PAH-specific therapies, such as endothelin receptor antagonists (ERAs), phosphodiesterase type 5 inhibitors (PDE5i), and prostacyclin analogs, target pulmonary artery pressure and ameliorate symptoms associated with PAH (7).

In the quest for innovative treatment modalities, molecular hydrogen (H2) therapy has emerged as a promising approach due to its unique biological properties. Molecular hydrogen exerts its effects through various mechanisms, including antioxidant, anti-inflammatory, anti-apoptotic, and gene expression modulation (8). Importantly, H2 is naturally occurring and non-toxic at therapeutic concentrations, making it suitable for long-term use (9). Research into H2 therapy spans across diverse medical conditions, including stroke, myocardial ischemia-reperfusion injury, chronic kidney disease, diabetes, and chronic obstructive pulmonary disease (COPD) (10-13). A crucial mechanism through which H2 exerts its therapeutic effects is by the activation of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2). Nrf2 is known for enhancing the transcription of a broad range of anti-stress enzymes, including antioxidant enzymes. The activation of Nrf2 by H2 involves a complex interaction with hydroxyl radicals (•OH) and heme (PrP-Fe(II)). Initially, the hydroxyl radical oxidizes heme, forming PrP-Fe(III)-OH, which subsequently reacts with H2 to produce PrP-Fe(III)-H and water. The PrP-Fe(III)-H complex acts as an electrophile that oxidizes Kelch-like ECH-associated protein 1 (Keap1), triggering the release and activation of Nrf2. This pathway enables H2 to indirectly mitigate oxidative stress by activating Nrf2 and its downstream antioxidant responses (14).

The hydrogen capsule is formulated by immobilizing hydrogen on the surface of coral calcium, primarily derived from coral exoskeletons. This method ensures stable delivery of hydrogen and demonstrates antioxidative properties (13, 15). A study evaluated the safety and lipid-lowering effects of hydrogen capsule in patients with metabolic syndrome, suggesting potential benefits in reducing lipid levels (13). In an experiment using a methionine-and-choline-deficient (MCD) diet-induced non-alcoholic fatty liver disease (NAFLD) mouse model, hydrogen capsules were found to alleviate lipid accumulation and liver dysfunction. The study further highlighted the antioxidative and anti-inflammatory effects of hydrogen capsule (15). The hydrogen capsule has demonstrated efficacy in decreasing ethanol-induced hepatic inflammation and alleviating alcohol hangover symptoms in mice, which includes reduced levels of pro-inflammatory cytokines, such as TNF-α, IL-6, and CCL2 (16). Another study observed a significant increase in resting regulatory T cell levels following hydrogen capsule treatment, along with a notable decrease in Fas+ helper T cells and cytotoxic T cell subtypes in a patient with PF-ILD complicated by pneumonia (17). These findings underscore the diverse therapeutic potential of hydrogen capsules, encompassing antioxidative, anti-inflammatory, and lipid-lowering properties, particularly in the contexts of liver health, lung disease and metabolic syndrome.

This article presents a case study of a 56-year-old female diagnosed with CTD-PAH awaiting lung transplantation. Despite receiving standard treatments, the condition remained unresponsive, prompting the initiation of hydrogen therapy as an adjuvant treatment (18, 19). This study was approved by the Institutional Review Board (IRB) of Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, and complied with relevant guidelines (IRB: B202105106, approval date: 18 July 2023). Written informed consent was obtained from all patients (No. B202105106-24). The study adhered to the ethical standards of the institution and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Case Report

A 56-year-old female patient presented with complaints of dyspnea that required oxygen supplementation. Her medical history dates back to July 2013 when she was hospitalized in the chest ward for dyspnea and cough with yellow sputum. She was subsequently diagnosed with Sjogren’s syndrome (20) complicated with interstitial lung disease (ILD) (21) and PAH (22) (Table I). Her chest X-ray at that time showed vascular markings with interstitial thickening, costophrenic (CP) angle blunting and cardiomegaly (Figure 1A). An echocardiogram revealed a pulmonary arterial (PA) systolic pressure of 99 mmHg, enlargement of the right atrium and ventricle, D-shaped left ventricle (LV), and severe tricuspid regurgitation. Chest CNYCT showed no filling defects, excluding pulmonary embolism; it also displayed an enlarged pulmonary trunk, right atrium (RA), and right ventricle (RV), further evidencing pulmonary hypertension (Figure 1E and F). Symptoms of dry mouth, dry eyes, and cracked tongue mucosa, with a Schirmer’s test showing <5 cm, oculus uterque (OU). A positive minor salivary gland biopsy, nuclear medicine scan showing impaired salivary gland function, and a positive anti-Ro test, confirmed Sjogren’s syndrome (Table I) (20). She started on Revatio (Sildenafil) (Figure 2) 20 mg three times a day (TID) for pulmonary hypertension control, adding Tracleer (Bosentan) (Figure 2) in 2016 due to disease progression (7). A right heart catheterization (RHC) revealed a mean pulmonary arterial pressure (PAP) of 39 mmHg, pulmonary vascular resistance (PVR) nearly 15 Woods, and a wedge pressure of 4, indicating pre-capillary type, group I, CTD-related PAH in 2017 (23). The right heart catheterization (RHC) report allowed for insurance coverage of Opsumit (Macitentan) (Figure 2) 10 mg once a day (QD), replacing Tracleer (Bosentan) in 2017. From 2017 to 2020, she was hospitalized multiple times for steroid treatments to manage her underlying Sjogren’s syndrome (6).

View this table:
Table I.

The illness of the patient on August 22, 2013 encompassed interstitial lung disease (ILD), Sjogren’s syndrome, and pulmonary arterial hypertension (PAH) complicated with heart failure (HF).

Figure 1.
Figure 1.

Clinical course of the patient. (A) CXR image on August 7, 2013, showing increased pulmonary vasculatures with interstitial lines thickening over bilateral lung fields. (B) CXR image on April 12, 2024, showing hazy opacities and bronchiectasis in bilateral lungs and reticulations in bilateral basal lungs. (C and D) High-resolution computed tomography (HRCT) images taken on August 2013 showing hazy ground-glass attenuation and thickening of interstitial lines. Chest computed tomography (CT) with contrast on August 2013 showing dilated pulmonary trunk with 4.04 cm, RA and RV.

Figure 2.
Figure 2.

The timeline of pulmonary hypertension therapy. The orange squares indicate the time of evaluation for lung transplantation and cardiogenic shock s/p ECMO and intubation. The blue square indicates the stable disease after adding molecular hydrogen as adjuvant therapy. Green color highlights the time molecular hydrogen was added.

Pulmonary hypertension treatment is risk-based (24), and until 2017 (Figure 2), the patient was considered low to intermediate risk, controlled with two medications (Sildenafil + Macitentan). Her condition remained stable until October 2020, when she experienced worsened dyspnea accompanied by cough and expectoration of white sputum, suggestive of infection. On November 10, 2020, the patient experienced severe dyspnea, cold sweats, and cyanosis, with SpO2 dropping to 70%, necessitating 100% O2 via face tent. Blood gas and lab tests revealed a lactate level of 5.2 mmol/l and brain natriuretic peptide (BNP) over 10,000 pg/ml, strongly suggesting cardiogenic shock. She was prepped for intensive care unit (ICU) admission, intubated, and initiated on four pulmonary hypertension medications (Figure 2). Her condition stabilized and showed improvement, preventing further deterioration. On November 12, 2020, evaluation for heart-lung transplantation began. Her condition continued to improve with off vasopressors on November 13, 2020, and extubating on November 14, 2020, and transferred to a general ward on November 21, 2020, with O2 tapered to nasal cannula 2l/min. A follow-up RHC continued to show elevated pulmonary artery pressure, likely attributed to chronic hypertension leading to right heart strain and eventual failure. After intensive care unit (ICU) treatment, she was referred to National Taiwan University Hospital for evaluation for heart-lung transplant.

Reviewing the records since the onset of her illness, it was evident that pulmonary artery pressure had steadily increased, and the distance covered in the 6-minute walk test was progressively shortened. Currently, the patient is classified as high risk. She continues regular hospitalizations for control. Despite the relatively stable condition, her chief complaint during the admission is still dyspnea. The physical examination revealed mild rhonchi ILD and a pansystolic murmur indicative of severe valvular heart disease, with no other significant findings. Ventavis (Iloprost) (Figure 2) 10 mcg/ml 2 ml was added in 2020. Molecular hydrogen therapy (1 capsule/day) was initiated in May 2023 (Figure 2). Hydrogen capsules (PURE HYDROGEN) were purchased from HoHo Biotech Co., Ltd. (Taipei, Taiwan, ROC). Each capsule contained 170 mg of hydrogen-rich coral calcium containing 1.7×1,021 molecules of hydrogen, which is equivalent to 24 cups of water with 1,200 ppb of hydrogen or 0.6 mM of hydrogen per 200 ml of water. Adjuvant therapy with hydrogen capsules resulted in increased CD127 + Treg, decreased anti-Ro antibody, decreased B cell subsets (Figure 3 and Figure 4), and stabilization of clinical symptoms and signs was observed following the addition of hydrogen therapy in this patient. No adverse reactions or events were observed following the administration of hydrogen capsules. Flow cytometry and serological examination were employed for whole-blood analysis to assess changes in immune cells and autoantibody before and after hydrogen therapy. For subsequent whole-blood analysis via flow cytometry, blood samples were prepared using standard fluorescent dye preparation methods and fluorescent antibody reagent kits with dried reagents (Beckman Coulter, Brea, CA, USA). The methods, steps, immunophenotypic analysis, and cell gating were conducted following previously described procedures (17, 25, 26). Our analysis of immunophenotypic markers before and after hydrogen therapy revealed increased CD127 + Treg and decreased B cell subsets after treatment (Figure 3). Moreover, this study adheres to the CARE reporting guidelines (2013 CARE Checklist).

Figure 3.
Figure 3.

Immunophenotypic changes before and after molecular hydrogen therapy. Whole-blood analysis was conducted nineteen times: prior to molecular hydrogen therapy (up to February 18, 2023) and post-therapy (from May 18, 2023 till March 25, 2024). (A) Percentage change in CD127+Treg that shows increasing trend after molecular hydrogen therapy. (B) Percentage change in Tr1 cell that shows increasing trend after molecular hydrogen therapy. (C) Percentage change in B cells CD21+ that shows decreasing trend after molecular hydrogen therapy. (D) Percentage change in plasma cell CD19+ IgM+ that shows decreasing trend after molecular hydrogen therapy. (E) Percentage change in switch memory B cells CD21+ that shows decreasing trend after molecular hydrogen therapy. (F) Percentage change in B cells HLADR+ that shows decreasing trend after molecular hydrogen therapy. (G) Percentage change in Plasma cell that shows decreasing trend after molecular hydrogen therapy. (H) Percentage change in plasmablasts CD19+IgM+ that shows decreasing trend after molecular hydrogen therapy. SM: Switch memory.

Figure 4.
Figure 4.

Immunophenotypic changes of anti-Ro antibodies before and after molecular hydrogen therapy. Whole-blood analysis was conducted twenty times: prior to molecular hydrogen therapy (up to March 6, 2023) and post-therapy (from May 18, 2023 till May 20, 2024). Anti-Ro antibodies show decreasing trend after molecular hydrogen therapy.

Discussion

This case study underscores the urgent need for novel interventions to treat cases of CTD-PAH. Despite approximately ten years of increasing pharmacological and non-pharmacological interventions, such as sildenafil, selexipag, macitentan, and iloprost, symptoms persisted without relief, ultimately requiring emergency measures due to cardiogenic shock (Figure 2). The observed increase in CD127+ regulatory T cells (Treg) following molecular hydrogen therapy suggests a potential immunomodulatory effect. CD127+ Treg cells play a crucial role in immune regulation and tolerance, and their expansion may contribute to dampening excessive immune responses implicated in CTD-PAH pathogenesis (27). This finding is consistent with prior research highlighting the anti-inflammatory properties of molecular hydrogen (8). The decrease in anti-Ro antibodies subsequent to molecular hydrogen therapy suggests a possible attenuation of autoimmune processes associated with CTD-PAH. Anti-Ro antibodies are frequently detected in autoimmune disorders like Sjogren’s syndrome (20) and have been associated with pulmonary vascular complications (28). The capacity of molecular hydrogen to modulate autoimmunity and reduce antibody production underscores its potential as a novel therapeutic approach in managing CTD-PAH. The reduction in B cell subsets indicates a modulation of B cell function through molecular hydrogen therapy. Dysregulated B cell responses have been implicated in the pathogenesis of autoimmune diseases and pulmonary hypertension (29). By targeting B cell subsets, molecular hydrogen may help mitigate aberrant immune activation and prevent further vascular damage in patients with CTD-PAH (30). Overall, the findings from this case study support the potential therapeutic benefits of molecular hydrogen in managing CTD-PAH. Through its anti-inflammatory and immunomodulatory effects, molecular hydrogen has shown promise in mitigating disease progression and enhancing clinical outcomes in patients resistant to conventional treatments. Moreover, the favorable safety profile of molecular hydrogen, as evidenced by the absence of adverse reactions in this study, highlights its potential as a well-tolerated adjunctive therapy for patients with CTD-PAH awaiting lung transplantation.

In conclusion, this case study highlights the effectiveness of hydrogen-assisted therapy for patients with CTD-PAH awaiting lung transplantation. Further research is necessary to elucidate the mechanisms underlying molecular hydrogen therapy and refine treatment protocols for optimal efficacy. Long-term prospective studies are warranted to assess the durability of treatment effects and evaluate its impact on disease prognosis and survival outcomes in CTD-PAH patients. Furthermore, randomized controlled trials comparing molecular hydrogen therapy with standard treatments are essential to validate its therapeutic potential and guide clinical practice guidelines for managing CTD-PAH. Although hydrogen-assisted therapy shows promise as a treatment option, future studies with larger sample sizes and long-term follow-up are needed to substantiate its efficacy and establish correlations between hydrogen therapy and CD127+ Treg cells, anti-Ro antibodies, and B cell subsets.

Conclusion

The therapeutic potential of molecular hydrogen is promising due to its multifaceted mechanisms of action, which include potent antioxidant, anti-inflammatory, and anti-apoptotic effects (8). The complex interaction involving the activation of Nrf2 by H2 suggests that H2 may mitigate oxidative stress indirectly by enhancing Nrf2 activity and its downstream antioxidant responses. Further investigation of Nrf2 in clinical settings may be warranted. The broad applications of molecular hydrogen across various diseases underscore its versatility and safety, warranting additional research into its potential as a novel treatment modality. This is particularly relevant in conditions like CTD-PAH, where oxidative stress and inflammation play crucial roles.

Acknowledgements

This study was supported by the Undergraduate Research Fellowship, Ministry of Science and Technology (MOST 111-2314-B-016-026), the National Science and Technology Council (NSTC 112-2314-B-016-033; NSTC 113-2314-B-016-052), Tri-Service General Hospital (TSGH-E-111215; TSGH-E-112218) in Taiwan.

Footnotes

  • Authors’ Contributions

    YTL: Conceptualization, methodology, writing – original draft, writing review and editing. JWL: Conceptualization, methodology, writing original draft, writing review and editing. YJH: Conceptualization, methodology, project administration, writing original draft, writing review and editing. SWL: Conceptualization, methodology, writing original draft, writing review and editing. TYH: Conceptualization, methodology, writing original draft, writing review and editing. FCL: Conceptualization, investigation, supervision, writing review and editing.

  • Conflicts of Interest

    The Authors declare no conflicts of interest or competing interests in relation to this study.

  • Received July 11, 2024.
  • Revision received July 29, 2024.
  • Accepted July 31, 2024.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. Khangoora V,
    2. Bernstein EJ,
    3. King CS,
    4. Shlobin OA
    : Connective tissue disease-associated pulmonary hypertension: A comprehensive review. Pulm Circ 13(4): e12276, 2023. DOI: 10.1002/pul2.12276
    OpenUrlCrossRefPubMed
  2. ↵
    1. Negrini S,
    2. Emmi G,
    3. Greco M,
    4. Borro M,
    5. Sardanelli F,
    6. Murdaca G,
    7. Indiveri F,
    8. Puppo F
    : Sjögren’s syndrome: a systemic autoimmune disease. Clin Exp Med 22(1): 9-25, 2022. DOI: 10.1007/s10238-021-00728-6
    OpenUrlCrossRefPubMed
  3. ↵
    1. Galiè N,
    2. Humbert M,
    3. Vachiery JL,
    4. Gibbs S,
    5. Lang I,
    6. Torbicki A,
    7. Simonneau G,
    8. Peacock A,
    9. Vonk Noordegraaf A,
    10. Beghetti M,
    11. Ghofrani A,
    12. Gomez Sanchez MA,
    13. Hansmann G,
    14. Klepetko W,
    15. Lancellotti P,
    16. Matucci M,
    17. McDonagh T,
    18. Pierard LA,
    19. Trindade PT,
    20. Zompatori M,
    21. Hoeper M, ESC Scientific Document Group
    : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37(1): 67-119, 2016. DOI: 10.1093/eurheartj/ehv317
    OpenUrlCrossRefPubMed
  4. ↵
    1. Dorfmüller P,
    2. Humbert M,
    3. Perros F,
    4. Sanchez O,
    5. Simonneau G,
    6. Müller KM,
    7. Capron F
    : Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 38(6): 893-902, 2007. DOI: 10.1016/j.humpath.2006.11.022
    OpenUrlCrossRefPubMed
  5. ↵
    1. Montani D,
    2. Günther S,
    3. Dorfmüller P,
    4. Perros F,
    5. Girerd B,
    6. Garcia G,
    7. Jaïs X,
    8. Savale L,
    9. Artaud-Macari E,
    10. Price LC,
    11. Humbert M,
    12. Simonneau G,
    13. Sitbon O
    : Pulmonary arterial hypertension. Orphanet J Rare Dis 8: 97, 2013. DOI: 10.1186/1750-1172-8-97
    OpenUrlCrossRefPubMed
  6. ↵
    1. Vij R,
    2. Strek ME
    : Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 143(3): 814-824, 2013. DOI: 10.1378/chest.12-0741
    OpenUrlCrossRefPubMed
  7. ↵
    1. Galiè N,
    2. Corris PA,
    3. Frost A,
    4. Girgis RE,
    5. Granton J,
    6. Jing ZC,
    7. Klepetko W,
    8. McGoon MD,
    9. McLaughlin VV,
    10. Preston IR,
    11. Rubin LJ,
    12. Sandoval J,
    13. Seeger W,
    14. Keogh A
    : Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 62(25 Suppl): D60-72, 2013. DOI: 10.1016/j.jacc.2013.10.031
    OpenUrlFREE Full Text
  8. ↵
    1. Ohta S
    : Molecular hydrogen as a preventive and therapeutic medical gas: initiation, development and potential of hydrogen medicine. Pharmacol Ther 144(1): 1-11, 2014. DOI: 10.1016/j.pharmthera.2014.04.006
    OpenUrlCrossRefPubMed
  9. ↵
    1. Ohsawa I,
    2. Ishikawa M,
    3. Takahashi K,
    4. Watanabe M,
    5. Nishimaki K,
    6. Yamagata K,
    7. Katsura K,
    8. Katayama Y,
    9. Asoh S,
    10. Ohta S
    : Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med 13(6): 688-694, 2007. DOI: 10.1038/nm1577
    OpenUrlCrossRefPubMed
  10. ↵
    1. Liu SL,
    2. Liu K,
    3. Sun Q,
    4. Liu WW,
    5. Tao HY,
    6. Sun XJ
    : Hydrogen therapy may be a novel and effective treatment for COPD. Front Pharmacol 2: 19, 2011. DOI: 10.3389/fphar.2011.00019
    OpenUrlCrossRefPubMed
    1. Fu Z,
    2. Zhang J
    : Molecular hydrogen is a promising therapeutic agent for pulmonary disease. J Zhejiang Univ Sci B 23(2): 102-122, 2022. DOI: 10.1631/jzus.B2100420
    OpenUrlCrossRefPubMed
    1. Johnsen HM,
    2. Hiorth M,
    3. Klaveness J
    : Molecular hydrogen therapy-a review on clinical studies and outcomes. Molecules 28(23): 7785, 2023. DOI: 10.3390/molecules28237785
    OpenUrlCrossRefPubMed
  13. ↵
    1. Zheng CM,
    2. Hou YC,
    3. Liao MT,
    4. Tsai KW,
    5. Hu WC,
    6. Yeh CC,
    7. Lu KC
    : Potential role of molecular hydrogen therapy on oxidative stress and redox signaling in chronic kidney disease. Biomed Pharmacother 176: 116802, 2024. DOI: 10.1016/j.biopha.2024.116802
    OpenUrlCrossRefPubMed
  14. ↵
    1. Ohta S
    : Molecular hydrogen may activate the transcription factor Nrf2 to alleviate oxidative stress through the hydrogen-targeted porphyrin. Aging Pathobiol Ther 5(1): 25-32, 2023. DOI: 10.31491/APT.2023.03.104
    OpenUrlCrossRef
  15. ↵
    1. Wu HT,
    2. Tsai CS,
    3. Chao TH,
    4. Ou HY,
    5. Tsai LM
    : A novel antioxidant, hydrogen-rich coral calcium alters gut microbiome and bile acid synthesis to improve methionine-and-choline-deficient diet-induced non-alcoholic fatty liver disease. Antioxidants (Basel) 13(6): 746, 2024. DOI: 10.3390/antiox13060746
    OpenUrlCrossRefPubMed
  16. ↵
    1. Wu HT,
    2. Chao TH,
    3. Ou HY,
    4. Tsai LM
    : Coral hydrate, a novel antioxidant, improves alcohol intoxication in mice. Antioxidants (Basel) 11(7): 1290, 2022. DOI: 10.3390/antiox11071290
    OpenUrlCrossRefPubMed
  17. ↵
    1. Lui SW,
    2. Lu JW,
    3. Ho YJ,
    4. Tang SE,
    5. Ko KH,
    6. Hsieh TY,
    7. Liu FC
    : Molecular hydrogen as a promising therapy could be linked with increased resting treg cells or decreased Fas+ T cell subsets in a IgG4-PF-ILD patient: a case report. In Vivo 38(3): 1512-1518, 2024. DOI: 10.21873/invivo.13600
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Tang C,
    2. Wang L,
    3. Chen Z,
    4. Yang J,
    5. Gao H,
    6. Guan C,
    7. Gu Q,
    8. He S,
    9. Yang F,
    10. Chen S,
    11. Ma L,
    12. Zhang Z,
    13. Zhao Y,
    14. Tang L,
    15. Xu Y,
    16. Hu Y,
    17. Luo X
    : Efficacy and safety of hydrogen therapy in patients with early-stage interstitial lung disease: a single-center, randomized, parallel-group controlled trial. Ther Clin Risk Manag 19: 1051-1061, 2023. DOI: 10.2147/TCRM.S438044
    OpenUrlCrossRefPubMed
  19. ↵
    1. Zolty R
    : Novel experimental therapies for treatment of pulmonary arterial hypertension. J Exp Pharmacol 13: 817-857, 2021. DOI: 10.2147/JEP.S236743
    OpenUrlCrossRefPubMed
  20. ↵
    1. Stefanski AL,
    2. Tomiak C,
    3. Pleyer U,
    4. Dietrich T,
    5. Burmester GR,
    6. Dörner T
    : The diagnosis and treatment of Sjögren’s syndrome. Dtsch Arztebl Int 114(20): 354-361, 2017. DOI: 10.3238/arztebl.2017.0354
    OpenUrlCrossRefPubMed
  21. ↵
    1. Luppi F,
    2. Sebastiani M,
    3. Silva M,
    4. Sverzellati N,
    5. Cavazza A,
    6. Salvarani C,
    7. Manfredi A
    : Interstitial lung disease in Sjögren’s syndrome: a clinical review. Clin Exp Rheumatol 38 Suppl 126(4): 291-300, 2020.
    OpenUrlPubMed
  22. ↵
    1. Maron BA,
    2. Galiè N
    : Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: a review. JAMA Cardiol 1(9): 1056-1065, 2016. DOI: 10.1001/jamacardio.2016.4471
    OpenUrlCrossRefPubMed
  23. ↵
    1. Anderson JJ,
    2. Lau EM
    : Pulmonary hypertension definition, classification, and epidemiology in Asia. JACC Asia 2(5): 538-546, 2022. DOI: 10.1016/j.jacasi.2022.04.008
    OpenUrlCrossRefPubMed
  24. ↵
    1. Corris PA
    : Risk stratification in PAH. Glob Cardiol Sci Pract 2020(1): e202009, 2020. DOI: 10.21542/gcsp.2020.9
    OpenUrlCrossRef
  25. ↵
    1. Lui SW,
    2. Hsieh TY,
    3. Lu JW,
    4. Chen YC,
    5. Lin TC,
    6. Ho YJ,
    7. Liu FC
    : Predicting the clinical efficacy of JAK inhibitor treatment for patients with rheumatoid arthritis based on Fas+ T cell subsets. APMIS 131(9): 498-509, 2023. DOI: 10.1111/apm.13341
    OpenUrlCrossRefPubMed
  26. ↵
    1. Hsieh TY,
    2. Lui SW,
    3. Lu JW,
    4. Chen YC,
    5. Lin TC,
    6. Jheng WL,
    7. Ho YJ,
    8. Liu FC
    : Using Treg, Tr1, and Breg expression levels to predict clinical responses to csDMARD treatment in drug-naive patients with rheumatoid arthritis. In Vivo 37(5): 2018-2027, 2023. DOI: 10.21873/invivo.13299
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Goswami TK,
    2. Singh M,
    3. Dhawan M,
    4. Mitra S,
    5. Emran TB,
    6. Rabaan AA,
    7. Mutair AA,
    8. Alawi ZA,
    9. Alhumaid S,
    10. Dhama K
    : Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders - Advances and challenges. Hum Vaccin Immunother 18(1): 2035117, 2022. DOI: 10.1080/21645515.2022.2035117
    OpenUrlCrossRefPubMed
  28. ↵
    1. Guerreso K,
    2. Conner EA
    : Possible role of anti-SSA/Ro antibodies in the pathogenesis of pulmonary hypertension. Respir Med Case Rep 17: 47-49, 2016. DOI: 10.1016/j.rmcr.2016.01.001
    OpenUrlCrossRefPubMed
  29. ↵
    1. Li J,
    2. Zhao M,
    3. Luo W,
    4. Huang J,
    5. Zhao B,
    6. Zhou Z
    : B cell metabolism in autoimmune diseases: signaling pathways and interventions. Front Immunol 14: 1232820, 2023. DOI: 10.3389/fimmu.2023.1232820
    OpenUrlCrossRefPubMed
  30. ↵
    1. Funk-Hilsdorf TC,
    2. Behrens F,
    3. Grune J,
    4. Simmons S
    : Dysregulated immunity in pulmonary hypertension: from companion to composer. Front Physiol 13: 819145, 2022. DOI: 10.3389/fphys.2022.819145
    OpenUrlCrossRefPubMed
View Abstract
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Molecular Hydrogen Therapy in Sjögren’s Syndrome With Pulmonary Arterial Hypertension and Right-sided Heart Failure: A Case Report of Improved Immune Markers Including Treg, B Cells and Plasma Cell
YUN-TING LIN, JENG-WEI LU, CHUN-HSIEN WU, YI-JUNG HO, SHAN-WEN LUI, TING-YU HSIEH, FENG-CHENG LIU
In Vivo Nov 2024, 38 (6) 3117-3124; DOI: 10.21873/invivo.13797
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords